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Abstract
Identification of biomarkers for the Alzheimer’s disease is a challenge
and a very difficult task both for medical research and data analysis.
In this work we present results obtained by application of a novel clus-
tering tool. The goal is to identify subpopulations of the Alzheimer’s
disease (AD) patients that are homogeneous in respect of available clini-
cal and biological descriptors. The result presents a segmentation of the
Alzheimer’s disease patient population and it may be expected that within
each subpopulation separately it will be easier to identify connections be-
tween clinical and biological descriptors. Through the evaluation of the
obtained clusters with AD subpopulations it has been noticed that for
two of them relevant biological measurements (whole brain volume and
intracerebral volume) change in opposite directions. If this observation
is actually true it would mean that the diagnosed severe dementia prob-
lems are results of different physiological processes. The observation may
have substantial consequences for medical research and clinical trial de-
sign. The used clustering methodology may be interesting also for other
medical and biological domains.
1 Introduction
Identification of connections between biological and clinical characteristics of
Alzheimer’s disease patients is a long term goal that could significantly improve
the understanding of the Alzheimer’s disease (AD) pathophysiology, improve
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clinical trial design, and help in predicting outcomes of mild cognitive impair-
ment [1]. The difficulty of the task is in the fact that AD is clinically described as
a set of signs and symptoms that can be only indirectly measured and that have
been integrated into various scoring systems like Clinical Dementia Rating Sum
of Boxes, Alzheimer’s Disease Assessment Scale, and Montreal Cognitive Assess-
ment [2]. All of these scales as well as everyday cognition problems have proved
their usefulness in the diagnostic process but a unique reliable measure does not
exist. On the other side, although relations between some biological descriptors
and AD diagnosis have been undoubtedly demonstrated [3, 4], currently avail-
able biological descriptors are non-specific (e.g., whole brain or hippocampal
volume) and their changes may be a consequence of various physiological pro-
cesses. It means that potentially useful information related to biological causes
of the cognitive status of a patient is hidden in the large “noise” of interfering
biological processes.
Technically speaking, we are looking for relevant relations in a very noisy
data domain (biological descriptors) in which the target function is defined by
a large set of imprecise values (clinical descriptors). A simplified approach in
which medical AD diagnosis is used as the target function has enabled the
detection of some relations, like importance of decreased FDG-PET values for
the AD diagnosis, but all the detected relations including those obtained by
complex supervised approaches [5] have low predictive quality and did not help
significantly in expert understanding of the disease. In line with the approach
proposed in [6], our work aims at finding homogeneous subpopulations of AD
patients in which it will be easier to identify statistically and logically relevant
relations between clinical and biological descriptors. The approach is based on
finding subpopulations with clustering algorithms.
Clustering is a well-established machine learning methodology but it still
suffers from problems such as definition of the distance measure and optimal
selection of the number of resulting clusters. Typically the obtained clustering
results are unstable because they significantly depend on user selectable param-
eters. This is especially true for noisy domains and domains with statistically
related descriptors (attributes). Recently we have developed a novel clustering
approach called multilayer clustering that successfully solves some of the basic
problems of data clustering [7]. In this methodology, the quality of the resulting
clusters is ensured by the constraint that clusters must be homogeneous at the
same time in two or more data layers, i.e., two or more sets of distinct data
descriptors. By defining the clinical descriptors as one data layer and biological
descriptors as the other layer, we can expect not only more reliable clusters but
clusters which will be potentially good candidates for the detection of relevant
relations between the clinical and biological descriptors. The AD domain ful-
fils all the requirements of the ideal setting in which multilayer clustering may
demonstrate its advantages.
The rest of the paper is structured as follows. Section 2 presents the mul-
tilayer clustering methodology, and Section 3 presents the concrete results for
the AD domain. Medical meaning and the results significance are analysed in
Section 4.
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2 Multilayer clustering
Clustering is an optimisation task which tries to construct subpopulations of
instances so that distances between instances within each subpopulation are
small while distances between instances in different subpopulations are as large
as possible [8]. The most commonly used distance measure is the Euclidean
distance that is well defined for numerical attributes.
Redescription mining is a novel clustering approach in which the quality of
the results is ensured by the constraint that the resulting clusters must have
meaningful interpretations in at least two independent attribute layers [9]. It is
possible, and it occurs often, that some of the training instances remain outside
the identified clusters but the detected clusters are more likely really relevant.
A very important property of this approach is that the constructed clusters have
human interpretable descriptions in all attribute layers.
However, redescription mining has some issues as well. For the approach to
be applied, both numerical and nominal attributes have to be transformed into
a transactional form [10] or some on–the–fly approaches have to be implemented
[11]. Also, selection of the appropriate minimal necessary support level is not a
trivial task. Low values may result in unacceptably long execution times of the
algorithms and unreliability of the results, while too high values may prevent
detection of any useful clusters [12]. An even more serious problem is that in
all real life domains some level of attribute noise can be expected. In such cases
an error in a single attribute value may prevent the identification of correct
descriptions. Such an error does not only cause that the erroneous example is
not detected as a member of a cluster, but it causes the descriptions in different
attribute layers not to cover all the subsets of examples it would have covered
otherwise. As a result, some of the actual clusters may not be detected.
In this work we use an approach to more reliable clustering that reuses the
basic idea of redescription mining in a novel setting, proposed in [7]. The first
step is to determine the similarity of instances in each attribute layer indepen-
dently and then to search for clusters that satisfy similarity conditions for all
layers. The main characteristic of the approach is that the resulting clusters are
small but very coherent.
2.1 Single layer algorithm
Let us assume a basic clustering task in which we have only one layer of at-
tributes. The clustering approach consists of two steps. In the first step we
estimate pair-wise similarity between all examples in the training data set. In
the second step we use this similarity estimation in order to construct clusters.
Similarity estimation.
In the first step we compute the so called example similarity table (EST). It
is an N × N symmetric matrix, where N is the number of examples. All its
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values are in the [0, 1] range, where large values denote large similarity between
examples.
We start from the original set of N examples represented by nominal and
numerical attributes that may contain unknown values. We define an “artificial”
binary classification problem on a data set constructed as follows. The first
part consists of examples from the original set, these examples are labelled as
positive. The second part consists of the same number of examples which are
generated by randomly shuffling attribute values of original examples (within
each attribute separately), these examples are labelled as negative.
Next, we use supervised machine learning to build classifiers for discrimi-
nation between positive cases (original examples) and negative cases (examples
with shuffled attribute values). The goal of learning are not the predictive mod-
els themselves, but the resulting information on the similarity of the original
(positive) examples. Machine learning approaches in which we can determine
if some examples are classified “in the same way” (meaning they are somehow
similar) are appropriate for this task. For example, in decision tree learning
this means that examples fall in the same leaf node, while in covering rule set
induction this means that examples are covered by the same rule. In order
to statistically estimate the similarity of the examples, it is necessary to use a
sufficiently large number of classifiers. Additionally, a necessary condition for a
good result is that the classifiers are as diverse as possible and that each of them
is better than random. All these conditions are satisfied by Random Forest [13]
and Random Rules algorithms [14]. Here we use the later one with which we
construct a large number of rules (100,000) for each EST computation.
Finally, the similarity of examples is estimated so that for each pair of ex-
amples we count how many rules cover both examples. The example similarity
table presents the statistics for positive examples only. A pair of similar exam-
ples will be covered by many rules, while no rules or a very small number of
rules will cover pairs that are very different in respect of their attribute values.
The final EST values are normalised with the largest detected count value.
Clustering with the CRV score.
In the second step we use the EST values to perform a bottom-up clustering.
The agglomeration of clusters is guided by the Clustering Related Variability
(CRV) score [7]. The score measures the variability of the EST similarity values
in a cluster of examples with respect to all other clusters. It is defined as follows.
Let xij be the similarity between examples i and j from the EST matrix.
The CRV score of a single example i from cluster C is the sum of within cluster
and outside of cluster components: CRV(i) = CRVwc(i) + CRVoc(i), i ∈ C. The
two components are sums of squared deviations from the mean value within
(or outside of) cluster C: CRVwc(i) =
∑
j∈C(xij − xi,wc)2 and CRVoc(i) =∑
j /∈C(xij − xi,oc)2. Finally, the CRV score of cluster C is the mean value of
CRV (i) values of all examples in the cluster: CRV(C) =
∑
i∈C CRV(i)/|C|.
The clustering algorithm starts with each example being in a separate cluster
and then iteratively tries to merge clusters together. In each iteration for each
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possible pair of clusters we compute the potential variability reduction that
can be obtained by merging the clusters. The variability reduction of joining
clusters C1 and C2 is computed as: DIFF(C1, C2) = (CRV(C1)+CRV(C2))/2−
CRV(C2∪C2). The pair of clusters with the largest variability reduction is then
merged into a single cluster. The iterative process repeats until no pair of
clusters exists for which the variability reduction is positive. A more detailed
description of the algorithm including some examples can be found in [7].
The algorithm produces a hierarchy of clusters and, in contrast to most
other clustering algorithms, it has a very well defined stopping criterion. The
algorithm stops when additional merging of clusters cannot further reduce the
variability, measured by the CRV score. This means that the algorithm auto-
matically determines the optimal number of clusters and that some examples
may stay unclustered, i.e., some clusters may only include a single example.
2.2 Multilayer algorithm
The single layer approach for clustering presented in the previous section can be
easily extended to clustering in multi-layer domains. For each attribute layer we
compute the example similarity table independently. Regardless of the number
and type of attributes in different layers, the EST tables will always be N ×N
matrices, because the number of examples in all layers is the same.
After having all the EST tables, we proceed with the clustering. The clus-
tering procedure for multiple layers is basically the same as for a single layer,
except that we merge two clusters only if a variability reduction exists in all
layers. For each possible pair of clusters we compute potential variability re-
duction for all attribute layers. Then we find the minimal variability reduction
in all layers, and merge the pair of clusters for which this value is largest. As
previously, we only merge two clusters if the (minimal) variability reduction is
positive.
3 Data and results
Data used in the preparation of this article were obtained from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) database. ADNI is a long term project
aimed at the identification of biomarkers of the disease and understanding of the
related pathophysiology processes. The project collects a broad range of clinical
and biological data about patients with different cognitive impairment.1 In our
work we started from a set of numerical descriptors extracted from the AD-
NIMERGE table, the joined dataset from several ADNI data tables. We have
used baseline evaluation data for 916 patients in total with 5 different medi-
cal diagnoses: cognitive normal CN (187 patients), significant memory concern
1The ADNI was launched in 2003 by the National Institute on Aging (NIA), the Na-
tional Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug
Administration (FDA), private pharmaceutical companies and non-profit organizations
(http://www.adni-info.org and http://adni.loni.usc.edu).
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Table 1: Properties of five largest clusters. The clusters are ordered by the de-
creasing median value of the CDRSB score for patients included in the clusters.
Number of Distribution of diagnoses
Cluster patients AD LMCI EMCI SMC CN CDRSB
A 42 41 1 - - - 5.5
B 19 12 4 1 - 2 4.0
C 20 14 2 - - 4 3.75
D 34 10 6 5 5 8 2.5
E 27 6 3 1 6 11 0
SMC (106), early mild cognitive impairment EMCI (311), late mild cognitive
impairment LMCI (164), and Alzheimer’s disease AD (148). The patients are
described by a total of 10 biological and 23 clinical descriptors. Biological de-
scriptors are genetic variations of APOE4 related gene, PET imaging results
FDG-PET and AV45, and MRI volumetric data of: Ventricles, Hippocampus,
WholeBrain, Entorhinal, Fusiform gyrus, Middle temporal gyrus (MidTemp),
and intracerebral volume (ICV). Clinical descriptors are: Clinical Dementia Rat-
ing Sum of Boxes (CDRSB), Alzheimer’s Disease Assessment Scale (ADAS13),
Mini Mental State Examination (MMSE), Rey Auditory Verbal Learning Test
(RAVLT immediate, learning, forgetting, percentage of forgetting), Functional
Assessment Questionnaire (FAQ), Montreal Cognitive Assessment (MOCA) and
Everyday Cognition which are cognitive functions questionnaire filled by the pa-
tient (ECogPt) and the patient study partner (ECogSP) (Memory, Language,
Visuospatial Abilities, Planning, Organization, Divided Attention, and Total
score).
The clustering process started from one table with biological data consist-
ing of 916 rows and 10 columns and one table with clinical data consisting of
916 rows and 23 columns. Each of the two tables represented one attribute
layer. The information about medical diagnoses of the patients have not been
included into the tables with the intention to use it only for the evaluation of
the clustering results. The goal of the clustering process has been to identify
as large as possible groups of patients that are similar according to both layers,
i.e., biological and clinical characteristics.
The result is a set of five clusters. The largest among them includes 42
patients and the smallest only 19 patients. Table 1 presents the distribution of
medical diagnoses for patients included into the clusters. We notice that the
largest cluster A is very homogeneous. It has 42 patients and 41 of them have
diagnosis AD while only one has diagnosis LMCI. Least homogeneous clusters
are D and E.
We have identified the CDRSB score as the clinical characteristic that best
discriminates between the constructed clusters. The rightmost column in Ta-
ble 1 presents median CDRSB values for patients included in each cluster. Val-
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Table 2: Median values and standard deviations of biological descriptors dis-
criminating clusters A and C. Distinguishing values are typeset in bold. Actual
values for ICV, Whole brain, Fusiform, and MidTemp values are 1,000 times
larger than presented in the table.
Cluster FDG-PET AV45 ICV Whole Brain Fusiform MidTemp
A 4.37 / 0.52 1.45 / 0.13 1404 / 193 918 /121 15.4 / 2.7 15.6 /3.2
B 5.67 / 0.67 1.43 / 0.23 1372 / 149 935 /84 16.0 /2.7 17.8 / 2.5
C 5.55 / 1.06 1.35 / 0.25 1634 /126 1107 / 72 18.2 / 2.0 19.4 / 2.7
D 6.28 / 0.85 1.20 / 0.26 1453 / 230 1005 / 144 17.2 / 2.4 19.6 / 2.4
E 6.45 / 0.70 1.19 / 0.25 1445 / 174 1022 /93 18.0 / 3. 19.6 / 2.5
AD 5.36 / 0.75 1.42 / 0.21 1490 / 175 986 /115 16.4 / 2.5 17.6 / 3.2
CN 6.57 / 0.54 1.05 / 0.17 1483 /155 1051 /101 18.4 /2.3 20.5 / 2.4
ues above 3.0 demonstrate that patients in clusters A–C have problems with
severe dementia. Patients in cluster D typically have moderate to severe de-
mentia, while the majority of patients in cluster E do not have problems with
dementia.
3.1 Distinguishing properties of patients in clusters A and
C
For each cluster we have computed median values and standard deviations of
all biological and clinical descriptors. The intention is to identify distinguishing
properties of patients included in the clusters. It is worth focusing on clusters
that have either extremely high or extremely low median values or very low
standard deviation of some descriptor. In the former case the patients in the
cluster have this property (significantly) increased or decreased, while in the
later case most of the patients have very similar values of the descriptor. We
can also find a distinguishing descriptor that has both low standard deviation
and extreme median value. In all such situations we interpret the descriptor as
a distinguishing property.
Clusters A, B, and C are especially interesting because most of the included
patients have diagnosis AD and these clusters may be regarded as relatively
homogeneous subsets of the AD patient population. The difference between
clusters A and C turned out to be especially intriguing. Table 2 presents the
values of biological descriptors for which patients in clusters A and C have
distinguishing values. Presented are median values and standard deviations for
all five clusters as well as for the complete AD population consisting of 148
patients and the complete cognitive normal (CN) population of 187 patients.
These results demonstrate that the patients in cluster A have extremely low
values of the FDG-PET descriptor. The median for this cluster is 4.37 while
median for the complete AD population is 5.36 and the median for cognitive
normal patients is 6.57. Surprisingly, we can notice that the difference between
the median of AD patients in cluster A and the median of all AD patients is
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almost as large as the difference between the median of all AD patients and
the median of CN patients. Additionally, it must be noted that the patients in
cluster A have very small standard deviation for FDG-PET meaning that the
consistency of these small values is high. A similar pattern can be observed for
the AV45 descriptor. When compared with other clusters and with the whole
AD and CN populations, patients in cluster A have the largest median value
1.45 and the smallest standard deviation of 0.13 . We can conclude that cluster
A is characterized by outstandingly low FDG-PET values and outstandingly
high AV45 values.
In contrast to cluster A, cluster C is characterized by outstandingly high
values for ICV and Whole brain descriptors, which are typeset in bold in the
fourth and fifth column of Table 2, respectively. There is a substantial difference
between biological descriptors that characterize clusters A and C. For cluster
A the extreme values of FDG-PET and AV45 descriptors are relevant, while
for cluster C the median values of these descriptors change (compared to CN
patients) in the same direction but with less intensity. The situation with ICV
and Whole brain descriptors is very different. Median values of ICV for CN
and all AD patients are very similar: 1483 and 1490, respectively. Patients in
cluster C have a high median value of 1634, while patients in cluster A have a
low median value of 1404 that is lower than the CN median value. A similar
situation is with the Whole brain descriptor. CN patients have a median value
of 1051, patients in cluster C have an increased value of 1107, while patients in
cluster A have a very low median value equal to 918. Additionally, patients in
cluster C have a low standard deviation of ICV and Whole brain descriptors.
Differences between clusters A and C can also be seen in some other biological
descriptors. The rightmost two columns in Table 2 demonstrate that patients
in cluster A have very low Fusiform and MidTemp volumes. For patients in
cluster C these values are almost normal or only slightly decreased.
A good property of the multilayer clustering is that similarity of patients in
both attribute layers is needed if they are to be included in the same cluster.
Table 3 presents clinical descriptors with distinguishing values for patients in
cluster A. CDRSB is a distinguishing descriptor but it is not included in Table 3
because we have already demonstrated in Table 1 that it has very high values
for cluster A. The median value for the complete AD population for CDRSB
descriptor is 4.5 while the median value for cluster A is 5.5 with a low standard
deviation. Clinical descriptors with distinguishing values for patients in cluster
C are presented in Table 4.
4 Discussion
Very elaborate medical studies have recently shown that mild and severe cog-
nitive impairment as well as AD diagnosis are correlated with some measurable
changes in the human brain. Our results are completely in agreement with
these results. Firstly, it has been shown that the progressive reduction in fluo-
rodeoxyglucose positron emission tomography (FDG-PET) measurement of the
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Table 3: Median values and standard deviations of clinical descriptors char-
acteristic for patients in cluster A. Distinguishing values are typeset in bold.
Functional RAVLT Ecog SP
Cluster ADAS13 MOCA Assessment Perc. Forgetting Organization
A 35 / 8.5 14.5 / 4.9 16 / 6.8 100 / 10 3.17 / 0.76
B 28 / 11.1 17 / 5.2 11 / 8.3 100 / 26 2.83 / 1.07
C 28 / 10.7 19 / 5.0 12 / 9.0 100 / 35 3.08 / 1.07
D 19.5 / 11.8 21.5 / 5.3 6.5 / 7.0 63 / 37 1.83 / 1.03
E 10 / 8.8 25 / 3.6 0 / 4.8 42 / 35 1.00 / 0.94
AD 31 / 8.4 18 / 4.5 13 / 7.1 100 / 20 2.83 / 0.86
CN 9 / 4.5 26 / 2.4 0 / 0.6 31 / 27 1.00 / 0.42
Table 4: Median values and standard deviations of clinical descriptors char-
acteristic for patients in cluster C. Distinguishing values are typeset in bold.
Ecog Pt Ecog Pt Ecog SP
Cluster Memory Organization Divided Attention
A 2.12 / 0.80 1.45 / 0.72 3.00 / 0.74
B 2.38 / 0.89 1.67 / 0.55 3.25 / 0.96
C 2.62 / 0.85 1.73 / 0.78 3.50 / 1.06
D 1.88 / 0.61 1.33 / 0.57 2.00 / 1.08
E 1.75 / 0.65 1.00 / 0.63 1.00 / 0.95
AD 2.38 / 0.75 1.50 / 0.74 3.25 / 0.93
CN 1.50 / 0.44 1.00 / 0.38 1.00 / 0.48
regional cerebral metabolic rate for glucose is related with cognitive impairment
[3]. This follows from a series of increasing values in the second column of Ta-
ble 2 and how it nicely correlates with the decreasing values of the CDRSB score
(last column of Table 1) practically for all clusters A-E. Also, there is a recent
result presented in [4] which demonstrates that the increased values of Flor-
betapir F18-AV-45 PET (AV45) are positively correlated with dementia. This
effect can be noticed in the third column of Table 2 where we have constantly
increasing values for clusters A–E in the order of their cognitive impairment
severity.
There is a statistical analysis of ADNI data which demonstrated that whole
brain atrophy and ventricular enlargement differ between cognitive impaired
patients and healthy controls [15]. The result is very interesting because it is
based on the same data source as our analysis. Our analysis detected the same
relation for clusters A, B, D, and E. So it is not surprising that in [15] this
property has been detected for the complete AD population. In our results the
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lowest median value for the whole brain volume is for cluster B (1372) but it is
also very low for cluster A (1404). The real novelty of our result is cluster C in
which the corresponding median value of 1107 is higher than in all other clusters
and also higher in than in the complete cognitive normal population with median
value of 1051.
This result is important because it potentially suggests that we have two
different AD related physiological processes. One, that results in significantly
decreased IC and whole brain volumes and is characteristic for the majority of
AD patients, and second, that results in increased IC and whole brain volumes
and appears in only 10-15% of cases. If this hypothesis is actually true, it will
have substantial consequences for medical research and treatment of Alzheimer’s
disease. Namely, it is very likely that each of the two physiological processes
will require different research and treatment procedures.
An additional result of our analysis is an observation that decreased FDG-
PET values, increased AV45 values and decreased whole brain volume are espe-
cially characteristic for cluster A that is the largest and most homogeneous AD
subpopulation. So it is not a surprise that these properties have been previously
recognized as relevant for the complete AD population [3, 4, 15]. But if these
studies would have concentrated on the AD subpopulation in cluster A only,
the statistical significance and usefulness of their results would most probably
be even higher.
Especially interesting is the question whether different physiological devel-
opment of the AD disease may affect the clinical status of the patient and the
patient’s clinical prognosis. Figure 1 illustrates the differences between clusters
A and C for ICV and ADAS13 values. Black circles denote patients in cluster A
while empty squares are patients in cluster C. Signs + and – denote the position
of median values for the whole AD and CN populations, respectively. The big
black circle is the median value for cluster A patients and the big square is the
median value for cluster C patients. Results presented in Table 3 suggest that
patients characterized by decreased ICV, fusiform, whole brain, and MidTemp
results (type A patients) have clinically very intensive general picture of AD
identified by high values of CDRSB, ADAS13, MOCA, and Functional Assess-
ment Questioner scores. In contrast, patients characterized by increased ICV,
almost normal fusiform, slightly increased whole brain, and slightly decreased
MidTemp (type C patients) have main problems with Everyday cognition, espe-
cially with Memory, Organization, and Divided Attention (see Table 4). This is
potentially an interesting issue for further medical expert evaluation. A prelim-
inary observation is that type C patients have self-awareness and insight to the
condition. This pattern is not the usual course of classic AD where the level of
insight decreases as the disease progresses.
Four squares at the bottom of Figure 1 denote four patients with cognitive
normal diagnosis included into cluster C. This is a potentially interesting fact
suggesting that the physiological process of type C (increased IC and whole brain
volumes) may in a small number of patients, in spite of significant physiologi-
cal changes, result in only slightly changed clinical status, which is diagnosed
as cognitive normal. In contrast, the significant physiological changes result-
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Figure 1: Alzheimer’s disease patients in cluster A (circles) and those in cluster
C (squares) presented in the space defined by the ICV (Intracerebral Volume)
and ADAS13 (Alzheimer’s Disease Assessment Scale).
ing from the process of type A (low FDG-PET, high AV45), according to the
available data, practically always results in severe dementia diagnosed as AD.
5 Conclusions
This work presents the application of a novel clustering methodology to discover
relations between two distinct sets of descriptors. The result is a set of small
but homogeneous clusters of examples (patients). The main advantages of the
methodology are that it may be successfully used on instances described by both
numeric and nominal attributes and that it has a well-defined stopping crite-
rion. Additionally, its unique property is that the quality of clusters is ensured
by the requirement that examples must be similar in at least two different at-
tribute layers. As a consequence the resulting clusters present the segmentation
of the complete population where each subpopulation has some homogeneous
properties in both layers. AD domain is a good example of a task in which
relations between layers can be different or even contradictory for various sub-
populations. In such cases it is very difficult to identify relevant relations on
a complete population by classical statistical analysis and supervised machine
learning approaches. But after successful segmentation even a simple analysis
of median values and standard deviations may enable identification of relevant
relations.
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The most relevant problem of the methodology is that constructed clusters
are small and that they tend to be even smaller if more than two layers are
used. In the concrete AD domain we got some useful insight about less than a
half of AD patients and practically no insight about cognitive normal patients
and patients with mild impairment. Additionally, the methodology has high
time complexity, which is growing quadratically with the number of examples.
Because of this the methodology is currently applicable only to domains with
an order of 1,000 examples.
The results of the analysis are potentially relevant medical hypotheses. It
will be necessary to extend the clinical measurements and to further study the
identified relations in order to confirm correctness of these hypotheses.
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